McKinley Carter Wealth Services Inc. decreased its position in Celgene Co. (NASDAQ:CELG) by 54.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,426 shares of the biopharmaceutical company’s stock after selling 1,718 shares during the period. McKinley Carter Wealth Services Inc.’s holdings in Celgene were worth $127,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Weatherstone Capital Management boosted its position in shares of Celgene by 16.3% during the 4th quarter. Weatherstone Capital Management now owns 3,899 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 547 shares during the period. Dempze Nancy E boosted its position in shares of Celgene by 22.9% during the 4th quarter. Dempze Nancy E now owns 2,950 shares of the biopharmaceutical company’s stock worth $308,000 after purchasing an additional 550 shares during the period. Valeo Financial Advisors LLC boosted its position in shares of Celgene by 31.7% during the 4th quarter. Valeo Financial Advisors LLC now owns 2,291 shares of the biopharmaceutical company’s stock worth $239,000 after purchasing an additional 552 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Celgene by 22.9% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 3,000 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 558 shares during the period. Finally, Telemus Capital LLC boosted its position in shares of Celgene by 2.2% during the 4th quarter. Telemus Capital LLC now owns 26,123 shares of the biopharmaceutical company’s stock worth $2,727,000 after purchasing an additional 574 shares during the period. 75.30% of the stock is owned by institutional investors and hedge funds.
In other news, Director Gilla Kaplan sold 27,750 shares of the firm’s stock in a transaction on Friday, May 18th. The shares were sold at an average price of $78.66, for a total value of $2,182,815.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Mark J. Alles acquired 1,208 shares of Celgene stock in a transaction dated Wednesday, May 9th. The stock was purchased at an average price of $82.60 per share, for a total transaction of $99,780.80. Following the completion of the acquisition, the chief executive officer now directly owns 187,316 shares in the company, valued at approximately $15,472,301.60. The disclosure for this purchase can be found here. Insiders sold a total of 58,500 shares of company stock worth $4,608,365 over the last 90 days. Company insiders own 0.39% of the company’s stock.
A number of equities analysts recently weighed in on the stock. Standpoint Research raised shares of Celgene from a “hold” rating to a “buy” rating in a research report on Monday. ValuEngine cut shares of Celgene from a “hold” rating to a “sell” rating in a research report on Thursday, April 12th. Zacks Investment Research raised shares of Celgene from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research report on Tuesday, May 1st. BidaskClub raised shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Friday, May 25th. Finally, Sanford C. Bernstein raised shares of Celgene from a “market perform” rating to an “outperform” rating and set a $102.00 price objective for the company in a research report on Wednesday, May 23rd. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $123.02.
Shares of CELG opened at $79.44 on Wednesday. Celgene Co. has a twelve month low of $74.13 and a twelve month high of $147.17. The firm has a market capitalization of $56.34 billion, a PE ratio of 11.61, a PEG ratio of 0.49 and a beta of 1.45. The company has a current ratio of 2.53, a quick ratio of 2.36 and a debt-to-equity ratio of 3.92.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported $2.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.96 by $0.09. Celgene had a net margin of 20.73% and a return on equity of 72.92%. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.47 billion. During the same period last year, the business earned $1.68 EPS. The company’s revenue was up 19.4% on a year-over-year basis. equities analysts expect that Celgene Co. will post 7.63 EPS for the current year.
Celgene announced that its Board of Directors has authorized a share buyback plan on Thursday, May 24th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase up to 5.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.